Previous close | 8.40 |
Open | 8.20 |
Bid | 8.80 |
Ask | 9.20 |
Strike | 240.00 |
Expiry date | 2024-10-18 |
Day's range | 8.10 - 8.40 |
Contract range | N/A |
Volume | |
Open interest | 183 |
BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.